New DrugMaraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection
References (58)
- et al.
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
PLoS Med.
(2006) - et al.
Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection
J Acquir Immune Defic Syndr
(2001) - 2007 AIDS epidemic update [UNAIDS Web...
New antiretroviral drugs
Clin Microbiol Infect
(2003)- et al.
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA Study Group
J Infect Dis
(2004) - et al.
Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
J Infect Dis
(2001) - et al.
A new classification for HIV-1
Nature
(1998) - et al.
Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
Nature
(1996) - et al.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
Cell
(1996) - et al.
Association between CCR5 genotype and the clinical course of HIV-11 infection
Ann Intern Med
(1997)
Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: Experience in a drug development programme for maraviroc
Antivir Ther
(2007)
The entry of entry inhibitors: A fusion of science and medicine
Proc Natl Acad Sci U S A
(2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
Proc Natl Acad Sci U S A
(2002)
HIV-1 cell entry and advances in viral entry inhibitor therapy
J Clin Virol
(2003)
The potential for HIV fusion inhibition
Curr Opin Infect Dis
(2001)
The plasma membrane as a combat zone in the HIV battlefield
Genes Dev
(2000)
Maraviroc (UUK-427,857), a potent, orally bioavailable,and selective small-molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunode-ficiency virus type 1 activity
Antimi-crob Agents Chemother
(2005)
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS
Curr Opin Investig Drugs
(2007)
Efficacy of shortterm monotherapy with maraviroc, a new CCR5 ntagonist, n patients infected with HIV-1
Nat Med
(2005)
Access denied? The status of coreceptor inhibition to counter HIV entry
Expert Opin Pharmacother
(2007)
Assessment of the pharmaco-kinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
Br J Clin Pharmacol
(2008)
Species differences in the disposition of the CCR5 antagonist, UK-4427,857, a new potential treatment for HIV
Drug Metab Dispos
(2005)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bbound receptor for entry
J Virol
(2007)
Cited by (0)
Copyright © 2008 Published by Elsevier Inc.